Stem Cell Therapeutics Corp. Announces Appointment of Chief Financial Officer

CALGARY, ALBERTA, Oct 01, 2010 (MARKETWIRE via COMTEX News Network) --

Stem Cell Therapeutics Corp. (TSX VENTURE: SSS) ("SCT" or the "Company") wishes to announce the appointment of Michael Cook as Chief Financial Officer of the Company.

Mr. Cook has his Chartered Accountant and Chartered Business Valuator designations. He has over 15 years of business experience and has expertise in Corporate Finance, Private Equity, and Corporate Management. Mr. Cook brings a unique combination of skills and experience to the team at Stem Cell Therapeutics. Alan Moore, CEO of the Company remarked, "We are fortunate to have Mr. Cook in the key role of CFO and we welcome him to the management team."

About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp. is a public biotechnology company (TSX VENTURE: SSS) focused on the development and commercialization of drug-based therapies to treat central nervous system diseases. SCT is a leader in the development of therapies that utilize drugs to stimulate a patient's own resident stem cells. The Company's programs aim to repair brain and nerve function lost due to disease or injury. The Company's extensive patent portfolio of owned and licensed intellectual property supports the potential expansion into future clinical programs in numerous neurological diseases such as traumatic brain injury, multiple sclerosis, Huntington's disease, Alzheimer's disease, and ALS.

For further information on Stem Cell Therapeutics Corp., visit www.stemcellthera.com.